This federal contract award, valued at $4,206.61, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of 4566601984 units of the pharmaceutical product Fluticasone-Salmeterol 115-21 12GM, a respiratory medication used to treat asthma and chronic obstructive pulmonary disease (COPD).
The contract has a firm fixed-price delivery order structure and an ultimate completion date of December 4, 2024. This award is not associated with a set-aside program and is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, valued at $999,999,999.00. The IDC, known as the ECAT Generation V Program, enables Dakota Drug, Inc. to efficiently provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations.
Generated 3/4/25, 11:14 AM